CERS 250117 1.00P (CERS250117P1000) Stock Options, News & Quotes

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

CERS250117P1000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 24 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Top SA Quant-rated Medical Devices Stocks as Technicals Look Strong
Seeking AlphaJan 22 11:44 ET
TD Cowen Maintains Cerus(CERS.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsJan 14 08:34 ET · Ratings
TD Cowen Remains a Buy on Cerus (CERS)
TipRanksJan 14 07:57 ET · Ratings
Stifel Maintains Cerus(CERS.US) With Buy Rating, Maintains Target Price $3
Moomoo NewsJan 13 20:32 ET · Ratings
Positive Growth Outlook and Undervaluation Support Buy Rating for Cerus
TipRanksJan 13 20:07 ET · Ratings
Cerus Announces Preliminary 2024 Revenues Of $180.3M, Up 15% From 2023; 2025 Revenue Projected At $194M-$200M, Indicating 8%-11% Growth; IFC Revenue Grows 42% In 2024; 2025 IFC Revenue Predicted Between $12M-$15M; Anticipates LED Illuminator Launch In...
BenzingaJan 13 09:22 ET

Comments

Holy Cow 151170498

Jan 14 09:01

$Cerus (CERS.US)$

Holy Cow 151170498

Jan 13 09:47

$Cerus (CERS.US)$ up up up

Trytosaveabit

Dec 9, 2024 16:05

Update! Hmm.

$Cerus (CERS.US)$ Reuters· 4 mins ago
Cerus Corp - Extends Supply and Manufacturing Agreement With Porex Until Dec 31, 2027

我要向钱看

Oct 31, 2024 01:51

$Cerus (CERS.US)$ Financial Performance:
Cerus Corporation reported Q3 product revenue of $46 million, achieving a 16% year-over-year growth. The nine-month period product revenue summed up to $129.5 million, indicating an 18% increase from the prior year.
Notable improvements in product gross margins which reached 56.9% in Q3, a rise of 200 basis points from the prior year's same period, attributed primarily to reduced product and supply chain costs.
Operating expenses in Q3 amounted to $31.8...

Jaguar8

Oct 30, 2024 15:00

NEWS

$Cerus (CERS.US)$
Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods
Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million